Similar articles for PMID: 31192153

Year	Number of Results
2011	1
2013	2
2014	3
2015	3
2016	1
2017	7
2018	12
2019	18
2020	28
2021	28
2022	39
2023	22
2024	0

1

Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.

Ou DL, Lin YY, Hsu CL, Lin YY, Chen CW, Yu JS, Miaw SC, Hsu PN, Cheng AL, Hsu C. Ou DL, et al. Liver Cancer. 2019 May;8(3):155-171. doi: 10.1159/000489318. Epub 2018 Jun 22. Liver Cancer. 2019. PMID: 31192153 Free PMC article.

2

Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.

Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, Feng J, Wang M, Chen J, Liu L, Shan J, Shen J, Yang Z, Wang G, Zhou H, Prieto J, Ávila MA, Liu C, Qian C. Xiang J, et al. Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31. Gastroenterology. 2020. PMID: 31678303

3

Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL. Wu SP, et al. J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18. J Thorac Oncol. 2018. PMID: 29269008 Free article.

4

Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.

Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. Zhu Y, et al. Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419. Epub 2019 Mar 22. Gut. 2019. PMID: 30902885

5

Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8⁺ T cell activation to eradicate hepatocellular carcinoma.

Cheng CC, Ho AS, Peng CL, Chang J, Sie ZL, Wang CL, Chen YL, Chen CY. Cheng CC, et al. Int Immunopharmacol. 2022 Nov;112:109110. doi: 10.1016/j.intimp.2022.109110. Epub 2022 Aug 27. Int Immunopharmacol. 2022. PMID: 36037651

6

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.

Park DJ, Sung PS, Lee GW, Cho S, Kim SM, Kang BY, Hur W, Yang H, Lee SK, Lee SH, Jung ES, Seo CH, Ahn J, Choi HJ, You YK, Jang JW, Bae SH, Choi JY, Yoon SK. Park DJ, et al. Int J Mol Sci. 2021 Apr 29;22(9):4710. doi: 10.3390/ijms22094710. Int J Mol Sci. 2021. PMID: 33946835 Free PMC article.

7

In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.

Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F. Oba T, et al. J Immunother Cancer. 2021 May;9(5):e002432. doi: 10.1136/jitc-2021-002432. J Immunother Cancer. 2021. PMID: 34049930 Free PMC article.

8

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. Chen Y, et al. Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20. Hepatology. 2015. PMID: 25529917 Free PMC article.

9

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.

Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, Gao Q, Li T, Shim JH, Zhang C, Liu K, Lee MH. Wang Y, et al. Front Immunol. 2021 May 14;12:654463. doi: 10.3389/fimmu.2021.654463. eCollection 2021. Front Immunol. 2021. PMID: 34054817 Free PMC article.

10

Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.

Chiu DK, Yuen VW, Cheu JW, Wei LL, Ting V, Fehlings M, Sumatoh H, Nardin A, Newell EW, Ng IO, Yau TC, Wong CM, Wong CC. Chiu DK, et al. Gastroenterology. 2020 Aug;159(2):609-623. doi: 10.1053/j.gastro.2020.03.074. Epub 2020 Apr 8. Gastroenterology. 2020. PMID: 32275969

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year